QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to...
![](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
Livewire
QRXPharma just saw its market cap shrink 75% from $120mil to $30mil on the FDA saying 'no', as Matthijs smith warned Livewire yesterday: There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session...Whatever happens, overnight, it is not going to be pretty. This morning QRX reported: United States Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo, an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at this time. A terrible day for the company's investors.
2 topics
![Livewire Equities](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
The Livewire Equities feed brings you a range of insights that relate to Australian equities
Expertise
No areas of expertise
![Livewire Equities](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYTg9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--39e69bd3b68ed62cda736d78909192fa6b58850d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2RTNKbGMybDZaVjkwYjE5bWFXeHNXd2RwQWNocEFjZz0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--c306068f01ab83c3650795f1865f4e6da1f93433/LWM-icon-exclusive.png)
The Livewire Equities feed brings you a range of insights that relate to Australian equities
Expertise
No areas of expertise